How to rebuild the pharma operating model for an AI…

AI is no longer a future ambition for pharma. Organizations are investing across discovery, clinical development, commercial operations, and manufacturing. Yet many are finding that technology alone is not enough to unlock the value they expected.

The real challenge lies in the operating model. Legacy decision-making processes, fragmented knowledge, siloed teams, and governance structures built for a different era can prevent organizations from acting on the insights AI generates.

As the industry moves beyond experimentation, leaders face a critical question: can their organizations adapt quickly enough to turn AI-driven insights into meaningful business outcomes? This article explores how leading pharma organizations are rethinking decision-making, collaboration, and enterprise knowledge to accelerate innovation and realize greater value from their AI investments.

AI supercharges scientists and SMEs, allowing human ingenuity to focus on complex judgements rather than data processing.”

Erik Nordkamp Global head of life sciences at PA

From building connected knowledge architectures to enabling continuous, cross-functional decision-making, discover the organizational shifts required to move beyond AI adoption and create lasting competitive advantage in an increasingly complex healthcare landscape

The full article was first published in PharmExec.